Description
The U.S. Food and Drug Administration (FDA) is issuing a notice of intent to incorporate non-FSS (open market) items over $25,000 on a GSA order. The FDA plans to establish a single-award Blanket Purchase Agreement (BPA) with an estimated total maximum value of $9.6 million. The BPA will include a subset of open-market components valued at $103,374.42, including computer workstations, laboratory equipment, and software. The FDA is providing public notice of the non-Schedule components to be incorporated into the BPA and is seeking no competitive open-market quotations.
• The BPA will be awarded to Agilent Technologies, Inc.
• The non-Schedule components include software, laboratory equipment, and accessories.
• The FDA will evaluate the price reasonableness of the non-Schedule line items prior to final contract execution.
• The Contracting Officer will provide public disclosures regarding the incorporation of non-Schedule items.